Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. David J. Dingli, MD
|
|
Give Review
Dr. David J. Dingli works in the field of Hematology. He went to medical school at University of Malta School of Medicine. He received awards:"Fellow (FACP)". Doctor David J. Dingli, MD is a published doctor. He published 37 publications, including: 'The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.' Doctor David J. Dingli, MD is registered with Medicare and accepts Medicare payments.
Publications
- Outcomes of primary refractory multiple Myeloma and the impact of novel therapies.
- Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple Myeloma.
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Soluble suppression of tumorigenicity 2 (sST2), but not Galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and Tropo...
- Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma Cell dyscrasias.
- Dynamics of Leukemia Stem-like Cell Extinction in Acute Promyelocytic Leukemia.
- Long-term outcome of patients with multiple Myeloma-related advanced renal failure following auto-SCT.
- Trends in survival of patients with primary plasma cell Leukemia: a population based analysis.
- How we manage autologous stem Cell transplantation for patients with multiple myeloma.
- Imaging findings in 22 cases of Schnitzler Syndrome: characteristic para-articular osteosclerosis, and the "hot knees" sign differential diagnosis.
- Long-term Disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
- High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem Cell transplant.
- Phase 2 trial of intravenously administered plerixafor for stem Cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
- Continued improvement in survival in multiple Myeloma: changes in early mortality and outcomes in older patients.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cel...
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Implications of continued response after autologous stem Cell transplantation for multiple myeloma.
- A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple Myeloma.
- Outcomes of patients with POEMS Syndrome treated initially with radiation.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem Cell transplantation have superior outcomes compared with patients with multiple myelom...
- Second auto-SCT for treatment of relapsed multiple Myeloma.
- Refinement in patient selection to reduce treatment-related mortality from autologous stem Cell transplantation in amyloidosis.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem Cell mobilization.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- Ten-year survival after autologous stem Cell transplantation for immunoglobulin light chain amyloidosis.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene.
- Autologous stem Cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisc...
- Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple Myeloma: identification of patients needing therapy.
- Improvement in renal function and its impact on survival in patients with newly diagnosed multiple Myeloma.
- The prognostic significance of CD45 expression by clonal bone marrow plasma Cells in patients with newly diagnosed multiple myeloma.
Schools
University Of Malta Faculty Of Medicine and Surgery
St Luke39s Hospital
Mayo Grad School Med
West Glasgow University Hospsnhs
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Fellow (FACP)
Education
-
Mayo School of Graduate Medical Education -
University of Malta School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1891769766 | |
| NPPES Provider LastName | DINGLI | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 341.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 3.23 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1891769766 |
| Last Name Of The Provider | DINGLI |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Thomas E. Witzig, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Rajiv K. Pruthi, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. C Christopher Hook, MD |
|
|
Dr. Aref Al-Kali, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shernan G. Holtan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diane M. Pierson, DO |
|
|
Dr. Timothy J. Hobday, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Gregory A. Wiseman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tait D. Shanafelt, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Paul L. Swiecicki, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rahma M. Warsame, MD
This Doctor is OpenDoctor Recommended.
|